Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119

1.

Mediators of Inflammation-Driven Expansion, Trafficking, and Function of Tumor-Infiltrating MDSCs.

Tannenbaum CS, Rayman PA, Pavicic PG, Kim JS, Wei W, Polefko A, Wallace W, Rini BI, Morris-Stiff G, Allende DS, Hamilton T, Finke JH, Diaz-Montero CM.

Cancer Immunol Res. 2019 Aug 22. doi: 10.1158/2326-6066.CIR-18-0578. [Epub ahead of print]

PMID:
31439615
2.

Influence of High, Disperse API Load on Properties along the Fused-Layer Modeling Process Chain of Solid Dosage Forms.

Tidau M, Kwade A, Finke JH.

Pharmaceutics. 2019 Apr 22;11(4). pii: E194. doi: 10.3390/pharmaceutics11040194.

3.

A Mathematical Approach to Consider Solid Compressibility in the Compression of Pharmaceutical Powders.

Wünsch I, Finke JH, John E, Juhnke M, Kwade A.

Pharmaceutics. 2019 Mar 15;11(3). pii: E121. doi: 10.3390/pharmaceutics11030121.

4.

SOFTs - Structured orodispersible film templates.

Steiner D, Finke JH, Kwade A.

Eur J Pharm Biopharm. 2019 Apr;137:209-217. doi: 10.1016/j.ejpb.2019.03.001. Epub 2019 Mar 2.

PMID:
30836181
5.

Characterization of the 3D microstructure of Ibuprofen tablets by means of synchrotron tomography.

Neumann M, Cabiscol R, Osenberg M, Markötter H, Manke I, Finke JH, Schmidt V.

J Microsc. 2019 May;274(2):102-113. doi: 10.1111/jmi.12789. Epub 2019 Mar 19.

PMID:
30829393
6.

Model-based description of disintegration time and dissolution rate of nanoparticle-loaded orodispersible films.

Steiner D, Finke JH, Kwade A.

Eur J Pharm Sci. 2019 Apr 30;132:18-26. doi: 10.1016/j.ejps.2019.02.029. Epub 2019 Feb 20.

PMID:
30794870
7.

Characterization of Mechanical Property Distributions on Tablet Surfaces.

Cabiscol R, Finke JH, Zetzener H, Kwade A.

Pharmaceutics. 2018 Oct 12;10(4). pii: E184. doi: 10.3390/pharmaceutics10040184.

8.

Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.

Tzeng A, Diaz-Montero CM, Rayman PA, Kim JS, Pavicic PG Jr, Finke JH, Barata PC, Lamenza M, Devonshire S, Schach K, Emamekhoo H, Ernstoff MS, Hoimes CJ, Rini BI, Garcia JA, Gilligan TD, Ornstein MC, Grivas P.

Target Oncol. 2018 Oct;13(5):599-609. doi: 10.1007/s11523-018-0595-9.

PMID:
30267200
9.

Formation of long-term stable amorphous ibuprofen nanoparticles via antisolvent melt precipitation (AMP).

Melzig S, Finke JH, Schilde C, Kwade A.

Eur J Pharm Biopharm. 2018 Oct;131:224-231. doi: 10.1016/j.ejpb.2018.08.011. Epub 2018 Aug 25.

PMID:
30149060
10.

Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy.

Ornstein MC, Diaz-Montero CM, Rayman P, Elson P, Haywood S, Finke JH, Kim JS, Pavicic PG Jr, Lamenza M, Devonshire S, Dann P, Schach K, Stephenson A, Campbell S, Emamekhoo H, Ernstoff MS, Hoimes CJ, Gilligan TD, Rini BI, Garcia JA, Grivas P.

Urol Oncol. 2018 Sep;36(9):405-412. doi: 10.1016/j.urolonc.2018.02.018. Epub 2018 Mar 30. Review.

PMID:
29606341
11.

Novel strategies for the formulation and processing of poorly water-soluble drugs.

Göke K, Lorenz T, Repanas A, Schneider F, Steiner D, Baumann K, Bunjes H, Dietzel A, Finke JH, Glasmacher B, Kwade A.

Eur J Pharm Biopharm. 2018 May;126:40-56. doi: 10.1016/j.ejpb.2017.05.008. Epub 2017 May 19. Review.

PMID:
28532676
12.

Instant ODFs - Development of an intermediate, nanoparticle-based product platform for individualized medication.

Steiner D, Finke JH, Kwade A.

Eur J Pharm Biopharm. 2018 May;126:149-158. doi: 10.1016/j.ejpb.2017.04.014. Epub 2017 Apr 13.

PMID:
28414191
13.

MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model.

Diaz-Montero CM, Mao FJ, Barnard J, Parker Y, Zamanian-Daryoush M, Pink JJ, Finke JH, Rini BI, Lindner DJ.

Br J Cancer. 2016 Oct 11;115(8):920-928. doi: 10.1038/bjc.2016.263. Epub 2016 Aug 25.

14.

Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial.

Rini BI, Dorff TB, Elson P, Rodriguez CS, Shepard D, Wood L, Humbert J, Pyle L, Wong YN, Finke JH, Rayman PA, Larkin JM, Garcia JA, Plimack ER.

Lancet Oncol. 2016 Sep;17(9):1317-24. doi: 10.1016/S1470-2045(16)30196-6. Epub 2016 Aug 3.

PMID:
27498080
15.

Efficient production of nanoparticle-loaded orodispersible films by process integration in a stirred media mill.

Steiner D, Finke JH, Kwade A.

Int J Pharm. 2016 Sep 25;511(2):804-13. doi: 10.1016/j.ijpharm.2016.07.058. Epub 2016 Jul 28.

PMID:
27477101
16.

Definitive activation of endogenous antitumor immunity by repetitive cycles of cyclophosphamide with interspersed Toll-like receptor agonists.

Manrique SZ, Dominguez AL, Mirza N, Spencer CD, Bradley JM, Finke JH, Lee JJ, Pease LR, Gendler SJ, Cohen PA.

Oncotarget. 2016 Jul 12;7(28):42919-42942. doi: 10.18632/oncotarget.10190.

17.

Myeloid-derived suppressor cells: The green light for myeloma immune escape.

Malek E, de Lima M, Letterio JJ, Kim BG, Finke JH, Driscoll JJ, Giralt SA.

Blood Rev. 2016 Sep;30(5):341-8. doi: 10.1016/j.blre.2016.04.002. Epub 2016 Apr 12. Review.

18.

The effect of miscellaneous oral dosage forms on the environmental pollution of sulfonamides in pig holdings.

Stahl J, Zessel K, Schulz J, Finke JH, Müller-Goymann CC, Kietzmann M.

BMC Vet Res. 2016 Apr 1;12:68. doi: 10.1186/s12917-016-0688-6.

19.

GBM Derived Gangliosides Induce T Cell Apoptosis through Activation of the Caspase Cascade Involving Both the Extrinsic and the Intrinsic Pathway.

Mahata B, Biswas S, Rayman P, Chahlavi A, Ko J, Bhattacharjee A, Li YT, Li Y, Das T, Sa G, Raychaudhuri B, Vogelbaum MA, Tannenbaum C, Finke JH, Biswas K.

PLoS One. 2015 Jul 30;10(7):e0134425. doi: 10.1371/journal.pone.0134425. eCollection 2015.

20.

Myeloid derived suppressor cell infiltration of murine and human gliomas is associated with reduction of tumor infiltrating lymphocytes.

Raychaudhuri B, Rayman P, Huang P, Grabowski M, Hambardzumyan D, Finke JH, Vogelbaum MA.

J Neurooncol. 2015 Apr;122(2):293-301. doi: 10.1007/s11060-015-1720-6. Epub 2015 Jan 13.

PMID:
25579983
21.

Cellular uptake of coumarin-6 under microfluidic conditions into HCE-T cells from nanoscale formulations.

Pretor S, Bartels J, Lorenz T, Dahl K, Finke JH, Peterat G, Krull R, Al-Halhouli AT, Dietzel A, Büttgenbach S, Behrends S, Reichl S, Müller-Goymann CC.

Mol Pharm. 2015 Jan 5;12(1):34-45. doi: 10.1021/mp500401t. Epub 2014 Nov 26.

PMID:
25412253
22.

Circulating Type-1 Anti-Tumor CD4(+) T Cells are Preferentially Pro-Apoptotic in Cancer Patients.

Wesa AK, Mandic M, Taylor JL, Moschos S, Kirkwood JM, Kwok WW, Finke JH, Storkus WJ.

Front Oncol. 2014 Sep 29;4:266. doi: 10.3389/fonc.2014.00266. eCollection 2014.

23.

Physicochemical characterization of sildenafil-loaded solid lipid nanoparticle dispersions (SLN) for pulmonary application.

Paranjpe M, Finke JH, Richter C, Gothsch T, Kwade A, Büttgenbach S, Müller-Goymann CC.

Int J Pharm. 2014 Dec 10;476(1-2):41-9. doi: 10.1016/j.ijpharm.2014.09.031. Epub 2014 Sep 26.

PMID:
25261709
24.

The differential regulation of human ACT1 isoforms by Hsp90 in IL-17 signaling.

Wu L, Wang C, Boisson B, Misra S, Rayman P, Finke JH, Puel A, Casanova JL, Li X.

J Immunol. 2014 Aug 15;193(4):1590-9. doi: 10.4049/jimmunol.1400715. Epub 2014 Jul 14.

25.

Combination of sunitinib with anti-tumor vaccination inhibits T cell priming and requires careful scheduling to achieve productive immunotherapy.

Jaini R, Rayman P, Cohen PA, Finke JH, Tuohy VK.

Int J Cancer. 2014 Apr 1;134(7):1695-705. doi: 10.1002/ijc.28488. Epub 2013 Oct 8.

26.

In vitro and ex vivo toxicological testing of sildenafil-loaded solid lipid nanoparticles.

Paranjpe M, Neuhaus V, Finke JH, Richter C, Gothsch T, Kwade A, Büttgenbach S, Braun A, Müller-Goymann CC.

Inhal Toxicol. 2013 Aug;25(9):536-43. doi: 10.3109/08958378.2013.810315.

PMID:
23905970
27.

Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics.

Finke JH, Rayman PA, Ko JS, Bradley JM, Gendler SJ, Cohen PA.

Cancer J. 2013 Jul-Aug;19(4):353-64. doi: 10.1097/PPO.0b013e31829da0ae. Review.

28.

Controlling solid lipid nanoparticle adhesion by polyelectrolyte multilayer surface modifications.

Finke JH, Schmolke H, Klages CP, Müller-Goymann CC.

Int J Pharm. 2013 Jun 5;449(1-2):59-71. doi: 10.1016/j.ijpharm.2013.03.061. Epub 2013 Apr 13.

PMID:
23591009
29.

Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer.

Najjar YG, Finke JH.

Front Oncol. 2013 Mar 15;3:49. doi: 10.3389/fonc.2013.00049. eCollection 2013.

30.

Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape.

Cohen PA, Ko JS, Storkus WJ, Spencer CD, Bradley JM, Gorman JE, McCurry DB, Zorro-Manrique S, Dominguez AL, Pathangey LB, Rayman PA, Rini BI, Gendler SJ, Finke JH.

Immunol Invest. 2012;41(6-7):680-710. doi: 10.3109/08820139.2012.703745. Review.

31.

Inhibition of metastasis by HEXIM1 through effects on cell invasion and angiogenesis.

Ketchart W, Smith KM, Krupka T, Wittmann BM, Hu Y, Rayman PA, Doughman YQ, Albert JM, Bai X, Finke JH, Xu Y, Exner AA, Montano MM.

Oncogene. 2013 Aug 15;32(33):3829-39. doi: 10.1038/onc.2012.405. Epub 2012 Sep 10.

32.

Defining the critical hurdles in cancer immunotherapy.

Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Håkansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML.

J Transl Med. 2011 Dec 14;9:214. doi: 10.1186/1479-5876-9-214.

33.

Clinical and immunomodulatory effects of celecoxib plus interferon-alpha in metastatic renal cell carcinoma patients with COX-2 tumor immunostaining.

Schwandt A, Garcia JA, Elson P, Wyckhouse J, Finke JH, Ireland J, Triozzi P, Zhou M, Dreicer R, Rini BI.

J Clin Immunol. 2011 Aug;31(4):690-8. doi: 10.1007/s10875-011-9530-x. Epub 2011 Apr 13.

PMID:
21487892
34.

Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination.

Bose A, Taylor JL, Alber S, Watkins SC, Garcia JA, Rini BI, Ko JS, Cohen PA, Finke JH, Storkus WJ.

Int J Cancer. 2011 Nov 1;129(9):2158-70. doi: 10.1002/ijc.25863. Epub 2011 May 25.

35.

Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained.

Ko JS, Rayman P, Ireland J, Swaidani S, Li G, Bunting KD, Rini B, Finke JH, Cohen PA.

Cancer Res. 2010 May 1;70(9):3526-36. doi: 10.1158/0008-5472.CAN-09-3278. Epub 2010 Apr 20. Erratum in: Cancer Res. 2010 Jun 15;70(12):5196.

36.

Immunological response to renal cryoablation in an in vivo orthotopic renal cell carcinoma murine model.

Matin SF, Sharma P, Gill IS, Tannenbaum C, Hobart MG, Novick AC, Finke JH.

J Urol. 2010 Jan;183(1):333-8. doi: 10.1016/j.juro.2009.08.110.

PMID:
19914660
37.

Elevated levels of select gangliosides in T cells from renal cell carcinoma patients is associated with T cell dysfunction.

Biswas S, Biswas K, Richmond A, Ko J, Ghosh S, Simmons M, Rayman P, Rini B, Gill I, Tannenbaum CS, Finke JH.

J Immunol. 2009 Oct 15;183(8):5050-8. doi: 10.4049/jimmunol.0900259.

38.

GD3, an overexpressed tumor-derived ganglioside, mediates the apoptosis of activated but not resting T cells.

Sa G, Das T, Moon C, Hilston CM, Rayman PA, Rini BI, Tannenbaum CS, Finke JH.

Cancer Res. 2009 Apr 1;69(7):3095-104. doi: 10.1158/0008-5472.CAN-08-3776. Epub 2009 Mar 10.

39.

Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients.

Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, Golshayan A, Rayman PA, Wood L, Garcia J, Dreicer R, Bukowski R, Finke JH.

Clin Cancer Res. 2009 Mar 15;15(6):2148-57. doi: 10.1158/1078-0432.CCR-08-1332. Epub 2009 Mar 10.

40.

Enhancement in specific CD8+ T cell recognition of EphA2+ tumors in vitro and in vivo after treatment with ligand agonists.

Wesa AK, Herrem CJ, Mandic M, Taylor JL, Vasquez C, Kawabe M, Tatsumi T, Leibowitz MS, Finke JH, Bukowski RM, Bruckheimer E, Kinch MS, Storkus WJ.

J Immunol. 2008 Dec 1;181(11):7721-7.

41.

Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients.

Finke JH, Rini B, Ireland J, Rayman P, Richmond A, Golshayan A, Wood L, Elson P, Garcia J, Dreicer R, Bukowski R.

Clin Cancer Res. 2008 Oct 15;14(20):6674-82. doi: 10.1158/1078-0432.CCR-07-5212.

42.

Renal cell carcinoma tumors induce T cell apoptosis through receptor-dependent and receptor-independent pathways.

Das T, Sa G, Paszkiewicz-Kozik E, Hilston C, Molto L, Rayman P, Kudo D, Biswas K, Bukowski RM, Finke JH, Tannenbaum CS.

J Immunol. 2008 Apr 1;180(7):4687-96.

43.

GM1 and tumor necrosis factor-alpha, overexpressed in renal cell carcinoma, synergize to induce T-cell apoptosis.

Das T, Sa G, Hilston C, Kudo D, Rayman P, Biswas K, Molto L, Bukowski R, Rini B, Finke JH, Tannenbaum C.

Cancer Res. 2008 Mar 15;68(6):2014-23. doi: 10.1158/0008-5472.CAN-07-6037.

44.

Improving immunotherapy by conditionally enhancing MHC class I presentation of tumor antigen-derived Peptide epitopes.

Storkus WJ, Herrem C, Kawabe M, Cohen PA, Bukowski RM, Finke JH, Wesa AK.

Crit Rev Immunol. 2007;27(5):485-93. Review.

PMID:
18197809
45.

CXC chemokine ligand 9/monokine induced by IFN-gamma production by tumor cells is critical for T cell-mediated suppression of cutaneous tumors.

Gorbachev AV, Kobayashi H, Kudo D, Tannenbaum CS, Finke JH, Shu S, Farber JM, Fairchild RL.

J Immunol. 2007 Feb 15;178(4):2278-86.

46.

Tumor-induced oxidative stress perturbs nuclear factor-kappaB activity-augmenting tumor necrosis factor-alpha-mediated T-cell death: protection by curcumin.

Bhattacharyya S, Mandal D, Sen GS, Pal S, Banerjee S, Lahiry L, Finke JH, Tannenbaum CS, Das T, Sa G.

Cancer Res. 2007 Jan 1;67(1):362-70.

47.

GM2 expression in renal cell carcinoma: potential role in tumor-induced T-cell dysfunction.

Biswas K, Richmond A, Rayman P, Biswas S, Thornton M, Sa G, Das T, Zhang R, Chahlavi A, Tannenbaum CS, Novick A, Bukowski R, Finke JH.

Cancer Res. 2006 Jul 1;66(13):6816-25.

48.

Glioblastomas induce T-lymphocyte death by two distinct pathways involving gangliosides and CD70.

Chahlavi A, Rayman P, Richmond AL, Biswas K, Zhang R, Vogelbaum M, Tannenbaum C, Barnett G, Finke JH.

Cancer Res. 2005 Jun 15;65(12):5428-38.

49.

Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma.

Herrem CJ, Tatsumi T, Olson KS, Shirai K, Finke JH, Bukowski RM, Zhou M, Richmond AL, Derweesh I, Kinch MS, Storkus WJ.

Clin Cancer Res. 2005 Jan 1;11(1):226-31.

50.

Innovations and challenges in renal cancer: consensus statement from the first international conference.

Atkins MB, Avigan DE, Bukowski RM, Childs RW, Dutcher JP, Eisen TG, Figlin RA, Finke JH, Flanigan RC, George DJ, Goldberg SN, Gordon MS, Iliopoulos O, Kaelin WG Jr, Linehan WM, Lipton A, Motzer RJ, Novick AC, Stadler WM, Teh BT, Yang JC, King L.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6277S-81S. Review. No abstract available.

Supplemental Content

Loading ...
Support Center